INTEGRATED GENOMICS SHARED RESOURCE Director: Christina Harrington, Ph.D. ABSTRACT / PROJECT SUMMARY The Integrated Genomics Shared Resource (IGSR) brings together advanced sequencing, microarray, and real- time PCR technologies in an established core environment with demonstrated strengths in delivery of high- quality data and comprehensive user support. As an integrated resource for genomic technologies and expertise in the handling and processing of a wide range of RNA and DNA samples, the IGSR is able to advise Knight members on selection of genomic technology applications that best meet their research aims and then effectively support those choices. During the current funding period the IGSR has greatly expanded high-throughput sequencing resources and services, and currently provides a wide range of massively parallel sequencing (MPS) options, including exome and panel sequencing, whole genome sequencing, RNA Seq, ChIP Seq, and Methyl Seq, using an Illumina HiSeq 2500, an Illumina HiSeq 2000 upgraded for 2-lane flow cell rapid runs, and an Illumina NextSeq 500. The facility provides Knight members: 1) access to otherwise costly technology at a reasonable cost; 2) in-house consultation for project development, experimental design, and analysis of results; 3) highly standardized and quality-controlled assays and data preparation, including initial data processing and quality control; 4) rapid turnaround time for genomic services; and 5) a stable repository of sequencing and microarray data. Most importantly, the IGSR maintains a team of highly knowledgeable and experienced staff to support and deliver services and to assist researchers with project design, grant development, assay development, and research publication. The IGSR works closely with the Knight Biostatistics Shared Resource and other Knight and institutional investments in computational biology and informatics to insure accessible and secure data storage and to develop and support best practices for genomic data processing, analysis and interpretation. The IGSR will continue to work with the Knight and other OHSU stakeholders to identify and implement new technologies and assays that meet new research opportunities and evolving needs, including close collaboration with the Knight in providing tools and support needed by the new Knight early detection initiative.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA069533-20
Application #
9640130
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-07-01
Budget End
2019-06-30
Support Year
20
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Oregon Health and Science University
Department
Type
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Su, Yulong; Pelz, Carl; Huang, Tao et al. (2018) Post-translational modification localizes MYC to the nuclear pore basket to regulate a subset of target genes involved in cellular responses to environmental signals. Genes Dev 32:1398-1419
Gast, Charles E; Silk, Alain D; Zarour, Luai et al. (2018) Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival. Sci Adv 4:eaat7828
Krey, Jocelyn F; Scheffer, Deborah I; Choi, Dongseok et al. (2018) Mass spectrometry quantitation of proteins from small pools of developing auditory and vestibular cells. Sci Data 5:180128
Rozanov, Dmitri V; Rozanov, Nikita D; Chiotti, Kami E et al. (2018) MHC class I loaded ligands from breast cancer cell lines: A potential HLA-I-typed antigen collection. J Proteomics 176:13-23
Winters-Stone, Kerri M; Wood, Lisa J; Stoyles, Sydnee et al. (2018) The Effects of Resistance Exercise on Biomarkers of Breast Cancer Prognosis: A Pooled Analysis of Three Randomized Trials. Cancer Epidemiol Biomarkers Prev 27:146-153
Pennock, Nathan D; Martinson, Holly A; Guo, Qiuchen et al. (2018) Ibuprofen supports macrophage differentiation, T cell recruitment, and tumor suppression in a model of postpartum breast cancer. J Immunother Cancer 6:98
Xu, Li; Gordon, Ryan; Farmer, Rebecca et al. (2018) Precision therapeutic targeting of human cancer cell motility. Nat Commun 9:2454
Chen, Emerson Y; Blanke, Charles D; Haller, Daniel G et al. (2018) A Phase II Study of Celecoxib With Irinotecan, 5-Fluorouracil, and Leucovorin in Patients With Previously Untreated Advanced or Metastatic Colorectal Cancer. Am J Clin Oncol 41:1193-1198
Lane, Ryan S; Femel, Julia; Breazeale, Alec P et al. (2018) IFN?-activated dermal lymphatic vessels inhibit cytotoxic T cells in melanoma and inflamed skin. J Exp Med 215:3057-3074
Smith, Nicholas R; Swain, John R; Davies, Paige S et al. (2018) Monoclonal Antibodies Reveal Dynamic Plasticity Between Lgr5- and Bmi1-Expressing Intestinal Cell Populations. Cell Mol Gastroenterol Hepatol 6:79-96

Showing the most recent 10 out of 277 publications